CQC-regulated clinics & online consultations
Posted on October 29, 2026 by Sally-Anne Turner
You’ve been taking antipsychotic medication for months or years now. It’s helping manage your symptoms, keeping you stable and allowing you to function. But there’s a problem you didn’t anticipate when you started treatment. You’ve gained weight. Perhaps a stone at first, then two, then more. Your clothes don’t fit. Your GP mentions concerns about your blood sugar or cholesterol. You feel trapped between managing your mental health and worrying about your physical health.
Now you’re wondering whether weight loss injections might help. You’ve heard about Wegovy and Mounjaro and seen the results others have achieved. But you’re worried. Will these medications interact with your psychiatric treatment? Could they make your mental health worse? Will your psychiatrist even consider them?
These questions deserve clear, evidence-based answers.
The relationship between antipsychotic medications and weight gain is one of the most challenging issues in psychiatric treatment. Weight gain isn’t simply a matter of willpower. Some antipsychotics influence appetite, metabolism and energy levels, making weight management more difficult.
Understanding these effects helps explain why GLP-1 weight loss medications are being investigated as potential options for people experiencing antipsychotic-associated weight gain.
Antipsychotic medications work by influencing neurotransmitter systems in the brain, particularly dopamine and, for many medicines, serotonin.
These effects can help manage symptoms of conditions such as schizophrenia, bipolar disorder and, in some circumstances, severe depression.
However, certain antipsychotics also influence pathways involved in appetite, glucose regulation and metabolism.
Antipsychotic-associated weight gain involves several mechanisms, which vary between medications.
Some antipsychotics block histamine H1 receptors and influence serotonin receptors involved in appetite regulation. This can increase hunger and make it more difficult to feel satisfied after eating.
Certain medicines are also associated with changes in insulin sensitivity and glucose regulation, potentially increasing the risk of metabolic complications.
Sedation can make physical activity more difficult, while increased appetite may contribute to higher energy intake.
Some antipsychotics also raise prolactin levels, although the relationship between prolactin and weight gain is complex and does not explain all medication-related weight changes.
Importantly, not every antipsychotic causes these effects to the same extent.
The experience of weight gain can be frustrating, particularly when a medication is otherwise helping someone manage a serious mental health condition.
Not all antipsychotics affect weight equally.
Olanzapine and clozapine are among the medicines most strongly associated with weight gain and metabolic complications. Some patients experience substantial weight increases during the first months of treatment, although the amount varies considerably.
Quetiapine, risperidone and paliperidone can also contribute to weight gain.
Other antipsychotics, including aripiprazole, may have a lower average risk of weight gain than olanzapine or clozapine, but none should be assumed completely weight-neutral for every patient. The challenge is that the most appropriate psychiatric medication is not always the one with the lowest metabolic risk.
Clozapine, for example, has an important role in treatment-resistant schizophrenia. Changing an effective antipsychotic solely because of weight gain can carry risks, including the return of psychiatric symptoms. Any decision to switch, reduce or stop antipsychotic medication must be made with the prescribing psychiatric team. Our team cannot at this moment offer GLP-1’s who take clozapine, as this medication requires weekly blood tests to check toxicity levels.
Antipsychotic-associated weight gain can have consequences beyond changes in appearance.
It may contribute to increased risks of type 2 diabetes, high blood pressure, abnormal cholesterol levels and cardiovascular disease.
People living with severe mental illness can also experience inequalities in physical healthcare and have higher rates of certain long-term health conditions.
Medication-related metabolic effects are one factor among several that may contribute to these inequalities.
This is why physical health monitoring is an important part of psychiatric care.
NICE recommends regular assessment of weight, blood glucose, lipids and other relevant cardiovascular and metabolic indicators in people receiving antipsychotic treatment.
Weight gain can also affect confidence, body image and quality of life. These concerns deserve attention alongside psychiatric symptom management.
GLP-1-based weight loss medications are being studied as possible options for people experiencing weight gain associated with antipsychotic treatment.
Wegovy contains semaglutide, a GLP-1 receptor agonist.
Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors.
These medicines have licensed weight-management indications in the UK, subject to eligibility criteria and clinical assessment.
However, treating antipsychotic-induced weight gain as a separate indication is not the same as prescribing a medicine for its licensed weight-management indication.
Someone taking antipsychotics must still meet the relevant prescribing criteria, and the evidence for individual psychiatric medication combinations must be considered.
GLP-1-based medicines act on pathways involved in appetite regulation and glucose control.
They can reduce hunger, increase feelings of fullness and delay gastric emptying.
For some people taking antipsychotics, these effects may help address increased appetite and support weight management.
GLP-1 medicines also influence glucose regulation, which may be relevant where metabolic health is a concern.
However, they do not directly reverse every metabolic effect of antipsychotic medication.
Although GLP-1 medicines do not act primarily through the same receptor systems as antipsychotics, this does not mean clinically relevant interactions or complications are impossible.
The combination requires an individual medication review.
Research examining GLP-1 receptor agonists for antipsychotic-associated weight gain has produced encouraging findings.
Clinical studies involving medicines such as liraglutide and exenatide have reported improvements in weight or metabolic measures in some people taking antipsychotics.
Research involving newer medicines, including semaglutide, is developing.
However, studies vary in size, duration, psychiatric diagnoses, antipsychotic treatment and outcomes measured.
The evidence is therefore not sufficient to assume that every GLP-1 medicine will produce the same results in everyone taking antipsychotics.
Large weight-loss trials involving Wegovy and Mounjaro have demonstrated clinically meaningful average weight reductions in eligible populations.
But those results cannot automatically be applied to people taking antipsychotics, particularly where severe or unstable psychiatric conditions were excluded from trials.
Individual outcomes depend on several factors, including the medicine prescribed, dose, overall health, nutrition and ongoing psychiatric treatment.
One of the most important questions is whether weight loss injections can be used safely by someone with a serious mental health condition.
The answer requires consideration of both the regulatory evidence and the individual’s psychiatric history.
As covered in our comprehensive guide on weight loss injections and mental health, regulatory authorities have investigated concerns about depression, suicidal thoughts and self-harm among people taking GLP-1 medicines.
The MHRA concluded that the available evidence did not support a causal association between the GLP-1 medicines reviewed and depression, suicidal ideation or suicide.
This is reassuring, but it does not prove that every possible psychiatric effect has been excluded.
The MHRA continues to monitor safety information as new evidence becomes available.
The regulator also highlights important physical risks, including gastrointestinal side effects, dehydration and acute pancreatitis.
You can read the MHRA’s guidance on GLP-1 medicines for weight loss and diabetes for more information.
For someone taking antipsychotics, an additional consideration is that evidence specifically involving people with severe psychiatric conditions remains more limited than evidence from general weight-management populations.
If you have schizophrenia, schizoaffective disorder or bipolar disorder with psychotic features, you may be concerned that weight loss medication could affect your psychiatric symptoms.
GLP-1 medicines are not generally classified as stimulants, and their primary mechanism differs from that of antipsychotics.
However, this is not enough to guarantee that they cannot influence mental wellbeing or that psychiatric symptoms will remain stable.
Studies specifically evaluating psychosis, mania and relapse outcomes during GLP-1 treatment are more limited.
Your clinician should consider your current mental health, treatment history and the medicines you take.
New or worsening hallucinations, delusions, manic symptoms, significant mood changes or unusual behaviour require prompt clinical assessment, regardless of whether the weight loss medicine is thought to be responsible.
If you’re experiencing an acute psychiatric episode, additional assessment may be needed before introducing weight loss treatment.
For example, active psychosis, mania or severe depression may affect treatment planning, nutrition, medication adherence or the ability to manage side effects.
However, there is no universal MHRA rule requiring everyone to be psychiatrically stable for a particular number of months before starting GLP-1 treatment.
The decision should be individualised.
For some patients, stabilising an acute psychiatric condition may take priority. Others may be able to receive weight-management treatment with appropriate coordinated support.
A mental health diagnosis alone should not automatically exclude someone from treatment.
The safest approach to considering weight loss injections alongside antipsychotics involves communication between the relevant healthcare professionals.
Your psychiatrist, GP and weight-management prescriber may all have important information about your health.
If antipsychotic-related weight gain is affecting you, raise the issue with your psychiatrist or prescribing clinician.
Explain how weight changes are affecting your physical health, daily life and emotional wellbeing.
You can also ask whether you meet the eligibility criteria for medical weight management and whether a GLP-1-based treatment might be appropriate.
Your psychiatrist may want to review your current medication, metabolic health and psychiatric symptoms before advising on treatment options.
If there are concerns about starting weight loss injections, ask what those concerns are and whether additional monitoring or specialist input could help.
Where appropriate, and with your consent, your weight loss prescriber should communicate with your psychiatric team.
This helps ensure that everyone understands your medication list, psychiatric history and treatment goals.
It also makes it easier to identify potential interactions or changes requiring assessment.
At Bodyline, we offer specialised support for patients with mental health considerations, with treatment suitability assessed according to individual circumstances.
Any coordination with external psychiatric providers should be agreed as part of the patient’s care plan.
It would be inaccurate to say that GLP-1 medicines have no significant interactions with antipsychotics.
GLP-1-based treatments delay gastric emptying, which may affect the absorption of some oral medicines.
The clinical significance depends on the medicine involved.
For patients taking psychiatric medications, particularly those requiring careful dose management or therapeutic monitoring, this should be reviewed by the prescribing team.
Gastrointestinal side effects also deserve attention.
Constipation can occur with GLP-1 medicines, while some antipsychotics have their own effects on bowel function.
If you also take diabetes medications, your clinician should assess the risk of hypoglycaemia. Insulin or sulfonylurea doses may require adjustment, but this should never be done independently.
Understanding how treatment is started and monitored can help you prepare.
Wegovy and Mounjaro are generally started at lower doses and increased according to their individual licensed dosing schedules.
Gradual dose escalation helps improve gastrointestinal tolerability.
Your prescriber should follow the product-specific instructions rather than using a single dosing approach for all GLP-1 medicines.
If you’re taking antipsychotics, your clinician may recommend additional monitoring based on your psychiatric history and other medications.
Common early side effects include nausea, diarrhoea, constipation and vomiting.
These effects are often manageable, but persistent or severe symptoms require medical advice.
Monitoring should reflect your individual health needs.
It may include weight, blood pressure, blood glucose or HbA1c, lipid levels, nutritional intake and relevant psychiatric symptoms.
NICE provides detailed recommendations for physical health monitoring in people taking antipsychotics, including regular weight and metabolic assessments.
The NICE guideline on psychosis and schizophrenia in adults recommends monitoring weight, cardiovascular health and metabolic indicators during antipsychotic treatment.
There is no universal requirement for everyone taking both an antipsychotic and a GLP-1 medicine to attend weekly or fortnightly weight-management appointments.
The appropriate frequency depends on clinical need, treatment stage and the monitoring arrangements agreed between healthcare providers.
Report significant changes in mental health promptly rather than waiting for your next scheduled appointment.
Gastrointestinal side effects are among the most common problems associated with GLP-1 medicines.
If you’re taking an antipsychotic that also causes constipation, the combination may require particular attention.
Maintaining adequate nutrition and hydration is important, especially when appetite is reduced.
If you’re unable to keep fluids down, experience persistent vomiting or develop signs of significant dehydration, seek medical advice.
Severe, persistent abdominal pain, particularly if it radiates to the back, requires urgent assessment because it may indicate pancreatitis.
Do not assume that all abdominal symptoms are ordinary treatment side effects.
If fatigue becomes persistent or interferes with daily life, discuss it with your clinician. Medication effects, inadequate nutrition, sleep difficulties and other health conditions may contribute.
Any changes to medication doses should be clinician-led.
Weight loss with GLP-1 treatment varies considerably between individuals.
Some people lose weight steadily, while others experience periods of slower progress or weight plateaus.
There is no reliable monthly weight-loss figure that applies to everyone, particularly when someone is also taking antipsychotic medication.
A reduction in weight may improve certain health markers, but the extent of improvement depends on the individual’s starting health and other factors.
Treatment goals should consider overall health, including blood glucose, blood pressure, nutritional status, physical functioning and psychiatric wellbeing.
Weight loss should not come at the expense of adequate nutrition or mental health stability.
Some antipsychotic medicines require additional precautions when considering GLP-1-based weight management.
Clozapine is an important treatment for treatment-resistant schizophrenia, but it is also associated with weight gain and metabolic complications.
It requires specialist monitoring, including mandatory blood monitoring because of the risk of serious blood disorders.
However, one particularly important concern when considering GLP-1 medicines is bowel function.
Clozapine can cause gastrointestinal hypomotility, meaning movement through the intestines becomes abnormally slow.
This can lead to severe constipation, intestinal obstruction and other potentially life-threatening complications.
Because GLP-1 medicines can also cause constipation and delay gastric emptying, combining them with clozapine requires careful clinical assessment.
The NHS Specialist Pharmacy Service guidance on managing constipation in people taking clozapine explains why bowel monitoring and prompt treatment of constipation are essential.
If you’re taking clozapine, your psychiatric team should be involved before GLP-1 treatment is started.
Your clinicians may need to review your bowel habits, existing constipation treatment, medication history and any additional gastrointestinal risks.
Report constipation promptly.
Severe or persistent abdominal pain, a swollen abdomen, vomiting or other symptoms suggesting bowel obstruction require urgent medical assessment.
These symptoms must not be dismissed as routine GLP-1 side effects.
Research suggests that some GLP-1-based medicines may help with weight management in people taking clozapine, but this does not eliminate the need for careful monitoring.
Olanzapine is associated with a relatively high risk of weight gain and metabolic changes.
If you’ve experienced weight gain while taking it, discussing your concerns with your psychiatric team is appropriate.
Some research suggests that GLP-1 receptor agonists may help improve weight or metabolic measures in patients taking olanzapine.
However, treatment responses vary, and GLP-1 medicines do not reliably reverse every effect of olanzapine.
Your psychiatrist may also consider other approaches to metabolic health, including nutritional support, physical activity programmes or reviewing the antipsychotic treatment where clinically appropriate.
Metformin has been studied and used in the management of antipsychotic-associated weight gain, but whether it is suitable depends on individual circumstances and prescribing guidance.
Combining metformin with a GLP-1 medicine should not be presented as a standard solution for everyone taking olanzapine.
Any combination requires assessment of its indication, benefits, side effects and potential risks.
Some people use food to cope with stress, anxiety, low mood or other difficult emotions.
Antipsychotic-related increases in appetite may make these patterns more challenging for certain individuals.
If weight loss treatment reduces your appetite, your relationship with food may change.
For some people, this feels helpful. Others may find that established eating routines or coping strategies need adjusting.
However, it would be inaccurate to assume that everyone with serious mental illness uses food to manage emotions or that GLP-1 treatment inevitably removes an important coping mechanism.
If emotional eating is a concern, psychological support may help.
Cognitive behavioural therapy and other appropriate interventions can support the development of alternative coping strategies.
Weight loss treatment can affect everyday routines.
If you attend a day centre, live in supported accommodation or receive help with meals or medication, changes in appetite may be noticed by people supporting you.
Where appropriate, and with your consent, sharing relevant information with carers or support staff can help ensure that your nutritional needs are met.
However, you remain entitled to privacy and involvement in decisions about your own care.
If you require assistance with injections or medication management, this should be arranged safely and with appropriate training.
Weight management often involves ongoing treatment and support.
Understanding the longer-term implications is particularly important when antipsychotic medication is also being taken.
Some people regain weight after stopping GLP-1-based treatment.
This may be particularly relevant if factors contributing to weight gain, such as increased appetite associated with antipsychotic medication, remain present.
However, it is not possible to predict exactly how much weight someone will regain or whether everyone will need indefinite treatment.
The appropriate duration depends on the medicine, its licensed indication, treatment response, tolerability and clinical guidance.
Long-term treatment also requires consideration of cost, monitoring, side effects and overall health goals.
Although longer-term evidence is growing, it would be inaccurate to guarantee that these medicines remain equally effective indefinitely or that side effects always disappear.
Our guide on how long to stay on weight loss injections explores the considerations involved in ongoing weight management.
If your psychiatric team recommends changing or discontinuing an antipsychotic, your weight-management needs may also change.
However, stopping an antipsychotic does not guarantee that medication-associated weight gain will reverse or that weight loss can be maintained without additional treatment.
Weight is influenced by several factors, including metabolic health, eating patterns, physical activity and other medicines.
Antipsychotics should never be stopped solely to improve weight without appropriate psychiatric assessment.
Abrupt discontinuation or inappropriate dose reduction can increase the risk of withdrawal symptoms or psychiatric relapse.
Any changes to your psychiatric medication and weight-management treatment should be planned with the relevant prescribers.
GLP-1-based medicines can improve certain metabolic measures in appropriately selected patients.
Depending on the medicine and individual circumstances, these may include blood glucose control, weight and some cardiovascular risk factors.
However, the benefits demonstrated in general clinical trials cannot automatically be assumed to apply to every patient taking antipsychotics.
These medicines also do not remove the need for routine cardiovascular and metabolic monitoring.
For someone taking antipsychotics, weight management should form part of a broader physical healthcare plan that considers blood pressure, glucose, cholesterol, nutrition and overall cardiovascular risk.
Deciding whether to pursue weight loss medication while taking antipsychotics involves weighing the potential benefits and risks in your individual situation.
How well controlled are your psychiatric symptoms at present?
Are you experiencing any side effects from your antipsychotic that could affect weight-management treatment?
Have your weight, blood glucose, cholesterol and blood pressure been reviewed recently?
Do you meet the relevant eligibility criteria for weight loss medication?
Would your psychiatric team be willing to coordinate with your weight-management prescriber?
Have you discussed alternative approaches to managing antipsychotic-associated weight gain?
These questions can help guide a clinical conversation rather than acting as a checklist that automatically determines eligibility.
Weight loss while taking antipsychotics may be challenging, but outcomes vary.
It would be inaccurate to say that everyone taking these medicines will lose weight more slowly than other patients.
Some people may experience meaningful weight reduction with appropriate treatment, while others have a more modest response.
Preventing further weight gain, improving blood glucose or making daily activities easier may also be worthwhile outcomes.
The aim should be to improve physical health without compromising psychiatric care.
Support can make weight management easier, particularly when someone is managing multiple health conditions.
This may include help from your GP, psychiatrist, weight-management prescriber, dietitian or psychological therapist.
Some people also benefit from peer support or assistance with practical aspects of treatment.
The amount and type of support required will differ between individuals.
The important thing is having a treatment plan that reflects your needs, preferences and clinical circumstances.
Antipsychotic-associated weight gain can be a difficult side effect to manage.
It may affect physical health, confidence and quality of life, particularly when the medication responsible is also providing important psychiatric benefits.
GLP-1-based weight loss medicines may be an option for some people, and emerging research into antipsychotic-associated weight gain is encouraging.
However, these treatments are not automatically suitable for everyone taking antipsychotics.
The potential benefits need to be weighed against individual risks, including gastrointestinal complications, medication interactions and the need for psychiatric monitoring.
If you’re struggling with weight gain while taking antipsychotic medication, you don’t have to ignore the problem or make changes to your psychiatric treatment independently.
Discuss your concerns with your psychiatrist or GP and ask about the options available for managing your physical health.
Book a consultation today to find out whether medical weight management may be appropriate for you.
At Bodyline Clinic, our team can assess your medical history, current medications and treatment eligibility, with additional specialist input or coordination where clinically necessary.
The goal is to support your physical health while recognising the importance of maintaining appropriate mental health treatment.
BMI calculator
Enter your height and weight to work out your Body Mass Index in seconds.
Your BMI
Find out where you sit and what your options are
Your BMI
Our CQC-regulated clinical team will confirm your eligibility at consultation, in clinic or by video.
CQC regulated 4.8 on Trustpilot
If you'd like advice on your health and wellbeing, our team can talk you through the services we offer.
Explore our servicesWe'd recommend speaking to your GP, who can check everything is OK and offer the right support.
BMI ranges work differently for under 18s. Please speak to your GP for advice.
Please check your height and weight.
Contact us today
Find out more about how we can treat and support you to improve your health and wellbeing.
No-obligation advice from our CQC-regulated team, in clinic or by video.
